Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08CWE
|
|||
| Drug Name |
PMID27828716-Compound-19
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H19N9
|
|||
| Canonical SMILES |
CC1=CC(=NN1)NC2=NC(=NC(=N2)NC3=CC4=C(C=C3)C=NN4)CC5=CC=CC=C5
|
|||
| InChI |
1S/C21H19N9/c1-13-9-19(30-28-13)26-21-25-18(10-14-5-3-2-4-6-14)24-20(27-21)23-16-8-7-15-12-22-29-17(15)11-16/h2-9,11-12H,10H2,1H3,(H,22,29)(H3,23,24,25,26,27,28,30)
|
|||
| InChIKey |
OKPNIPFZIIYESG-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycogen synthase kinase-3 alpha (GSK-3A) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Glycogen synthase kinase-3 alpha (GSK-3A) | Target's Patent Info | [1] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Insulin/IGF pathway-protein kinase B signaling cascade | ||||
| PDGF signaling pathway | ||||
| Ras Pathway | ||||
| Pathway Interaction Database | Degradation of beta catenin | |||
| Canonical Wnt signaling pathway | ||||
| FOXM1 transcription factor network | ||||
| Class I PI3K signaling events mediated by Akt | ||||
| Reactome | AKT phosphorylates targets in the cytosol | |||
| XBP1(S) activates chaperone genes | ||||
| Constitutive Signaling by AKT1 E17K in Cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.